Shanghai Henlius Biotech, Inc. (2696.HK), a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co Ltd, announced on Thursday that the European Medicines Agency (EMA) has validated the application for the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab), in combination with chemotherapy (carboplatin and etoposide), intended for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
The European Commission (EC) has earlier granted Orphan Drug Designation (ODD) to the product for the treatment of small cell lung cancer (SCLC).
The company submitted the regulatory application based on data from ASTRUM-005, a randomised, double-blind, placebo-controlled international multi-centre phase three clinical study that assessed the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with ES-SCLC.
The study has set up 128 sites in various countries, including China, Poland, Turkey, and Georgia, and enrolled 585 subjects, among whom 31.5% were white. The results were presented orally at the 2022 ASCO annual meeting and were then published in the JAMA (impact factor of 157.3), demonstrating the high level of academic acclaim on a global scale.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration